Abstract
Mitochondria are known to play crucial roles in normal cellular physiology and in more recent years they have been implicated in a wide range of pathologies. Central to both these roles is their ability to alter their shape interchangeably between two different morphologies: an elongated interconnected network and a fragmented discrete phenotype - processes which are under the regulation of the mitochondrial fusion and fission proteins, respectively. In this review article, we focus on the mitochondrial fusion protein optic atrophy protein 1 (OPA1) in cardiovascular health and disease and we explore its role as a potential therapeutic target for treating cardiovascular and metabolic disease.
Keywords: Cardiovascular disease, fission, fusion, mitochondrial morphology, OPA1.
Current Drug Targets
Title:OPA1 in Cardiovascular Health and Disease
Volume: 16 Issue: 8
Author(s): Niall Burke, Andrew R. Hall and Derek J. Hausenloy
Affiliation:
Keywords: Cardiovascular disease, fission, fusion, mitochondrial morphology, OPA1.
Abstract: Mitochondria are known to play crucial roles in normal cellular physiology and in more recent years they have been implicated in a wide range of pathologies. Central to both these roles is their ability to alter their shape interchangeably between two different morphologies: an elongated interconnected network and a fragmented discrete phenotype - processes which are under the regulation of the mitochondrial fusion and fission proteins, respectively. In this review article, we focus on the mitochondrial fusion protein optic atrophy protein 1 (OPA1) in cardiovascular health and disease and we explore its role as a potential therapeutic target for treating cardiovascular and metabolic disease.
Export Options
About this article
Cite this article as:
Burke Niall, Hall R. Andrew and Hausenloy J. Derek, OPA1 in Cardiovascular Health and Disease, Current Drug Targets 2015; 16 (8) . https://dx.doi.org/10.2174/1389450116666150102113648
DOI https://dx.doi.org/10.2174/1389450116666150102113648 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toll-Like Receptors and Myocardial Ischemia/Reperfusion, Inflammation, and Injury
Current Cardiology Reviews Artificial Neural Networks in Cardiovascular Diseases and its Potential for Clinical Application in Molecular Imaging
Current Radiopharmaceuticals Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Atrial Fibrillation: The Emerging Role of Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design Characterizing the Bi-Subunit Type IB DNA Topoisomerase of Leishmania Parasites; a Novel Scenario for Drug Intervention in Trypanosomatids
Current Drug Targets How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart
Current Gene Therapy Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure
Current Signal Transduction Therapy Fontan Circulation Might be Associated with Peripartum Cardiomyopathy: A Review of Mechanistic and Clinical Aspects
Current Cardiology Reviews Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families
Endocrine, Metabolic & Immune Disorders - Drug Targets Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Tracking the Mesenchymal Stem Cell Fate After Transplantation Into the Infarcted Myocardium
Current Stem Cell Research & Therapy Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Effects of Statins on Transplant Graft Arterial Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)